Achilles Therapeutics Pl-adr(ACHL)
$1.070%
Insights
- Achilles Therapeutics Pl-adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Achilles Therapeutics Pl-adr stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, Achilles Therapeutics Pl-adr stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Achilles Therapeutics Pl-adr stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 61.68 | Sell |
Stochastic | 61.51, 62.79 | Neutral |
Ultimate Oscillator | 72.48 | Sell |
Stochastic Relative Strength Index | 69.37, 67.94 | Neutral |
Moving Average Convergence Divergence | 0.02, 0.02 | Sell |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 1.07 | Buy |
20 | 1.05 | Buy |
50 | 1.02 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 1.06 | Buy |
20 | 1.05 | Buy |
50 | 1.0 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 1.05 | Neutral |
20 | 1.06 | Neutral |
50 | 1.02 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 1.08 | Sell |
20 | 1.08 | Buy |
50 | 1.08 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 1.07 | Sell |
20 | 1.07 | Sell |
50 | 1.1 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 1.12 |
Resistance L2 | 1.1 |
Resistance L1 | 1.09 |
Pivot Point | 1.07 |
Support L1 | 1.06 |
Support L2 | 1.04 |
Support L3 | 1.03 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.